Intas Pharmaceuticals Ltd.

Intas Pharmaceuticals is a global leader in developing, manufacturing and marketing generics, biosimilars and added-value medicines, achieving $2.4 billion in sales in 2024-25 across more than 85 countries, with about two-thirds of revenue from international markets, especially the EU and US. Intas operates four GMP sites in India, two in the UK, one in Mexico and one in Greece, producing various pharmaceutical forms and maintaining vertical integration into APIs for key products, with a workforce of 19,000 employees.